The European Medicines Agency (EMA) granted marketing authorization in 2013 for treatment of disabling tophaceous gout.

[6] Pegloticase is given as an intravenous infusion every two weeks,[6] and has been found to reduce uric acid levels in this population.

[7] There is moderate quality evidence that It is useful for tophi but has a high rate of side effects and withdrawals due to adverse events.

This reduces the risk of urate precipitates, since allantoin is five to ten times more soluble than uric acid.

In contrast to rasburicase, pegloticase is PEGylated to increase its elimination half-life from about eight hours to ten to twelve days, and to decrease the immunogenicity of the foreign uricase protein.